Skip to Content

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

Chimeric antigen receptor (CAR) T cell therapy is a form of immunotherapy in which T cells are genetically engineered to express T cell receptors that target a specific protein. Since its FDA approval in 2017, CAR-T cell therapy was a staple treatment for blood cancers such as multiple myeloma. New cancer cell targets are being discovered continuously, allowing for further tailoring of CAR-T cells for a specific patient.

In the multicenter CARTBCMA-HCB-01 study (NCT04309981), the efficacy and safety of a novel autologous CAR T-cell product (ARI0002h) targeting B-cell maturation antigen (BCMA) were evaluated in patients with relapsed/refractory multiple myeloma.

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top